Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - budesonide; formoterol fumarate dihydrate - powder for inhalation - budesonide 100 mcg/dose; formoterol fumarate dihydrate 6 mcg/dose - formoterol and budesonide - budemol s.k. is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting betaagonist) is appropriate: - patients not adequaterly controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. - or patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. copd symptomatic treatment of patients with severe copd (fev1 < 50 % predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilator

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - budesonide; formoterol fumarate dihydrate - powder for inhalation - budesonide 200 mcg/dose; formoterol fumarate dihydrate 6 mcg/dose - formoterol and budesonide - budemol s.k. is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting betaagonist) is appropriate: - patients not adequaterly controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. - or patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. copd symptomatic treatment of patients with severe copd (fev1 < 50 % predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilator

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - budesonide; formoterol fumarate dihydrate - powder for inhalation - budesonide 400 mcg/dose; formoterol fumarate dihydrate 12 mcg/dose - formoterol and budesonide - budemol s.k. is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting betaagonist) is appropriate: - patients not adequaterly controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. - or patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. copd symptomatic treatment of patients with severe copd (fev1 < 50 % predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilator

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - dasatinib - film coated tablets - dasatinib 100 mg - dasatinib - dasatinib is indicated for the treatment of adult patients with:• newly diagnosed philadelphia-chromosome-positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase;• chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate;• ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - dasatinib - film coated tablets - dasatinib 140 mg - dasatinib - dasatinib is indicated for the treatment of adult patients with:• newly diagnosed philadelphia-chromosome-positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase;• chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate;• ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - dasatinib - film coated tablets - dasatinib 20 mg - dasatinib - dasatinib is indicated for the treatment of adult patients with:• newly diagnosed philadelphia-chromosome-positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase;• chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate;• ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - dasatinib - film coated tablets - dasatinib 50 mg - dasatinib - dasatinib is indicated for the treatment of adult patients with:• newly diagnosed philadelphia-chromosome-positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase;• chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate;• ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - dasatinib - film coated tablets - dasatinib 70 mg - dasatinib - dasatinib is indicated for the treatment of adult patients with:• newly diagnosed philadelphia-chromosome-positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase;• chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate;• ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - sunitinib - capsules - sunitinib 12.5 mg - sunitinib - sunitinib s.k. is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sunitinib s.k. is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Israel - English - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - sunitinib - capsules - sunitinib 25 mg - sunitinib - sunitinib s.k. is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sunitinib s.k. is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.